Johnson & Johnson (NYSE:JNJ) Shares Sold by Westbourne Investment Advisors Inc.

Westbourne Investment Advisors Inc. decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 1.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,469 shares of the company’s stock after selling 110 shares during the quarter. Westbourne Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $1,080,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. AMF Tjanstepension AB lifted its holdings in Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after buying an additional 52,997 shares during the last quarter. Alpha Financial Partners LLC bought a new position in Johnson & Johnson during the 3rd quarter worth approximately $209,000. Wealth Group Ltd. bought a new position in Johnson & Johnson during the 3rd quarter worth approximately $213,000. ORG Wealth Partners LLC bought a new position in Johnson & Johnson during the 3rd quarter worth approximately $226,000. Finally, Wedge Capital Management L L P NC lifted its holdings in Johnson & Johnson by 2.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 4,039 shares of the company’s stock worth $655,000 after buying an additional 86 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.3 %

Shares of JNJ stock opened at $156.18 on Wednesday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock has a market cap of $376.02 billion, a PE ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The business’s fifty day moving average is $147.40 and its 200-day moving average is $156.04. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the firm earned $2.29 EPS. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price on the stock. Barclays raised their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Morgan Stanley cut their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Finally, Raymond James cut their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $170.67.

Insider Buying and Selling

In related news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.